ECHO Resources

• Overview of medications for OUD
• Addiction Medicine Board Certification Certification Hub for Physicians (American Society of Addiction Medicine (ASAM))
• The ASAM Treatment of Opioid Use Disorder Course (American Society of Addiction Medicine (ASAM))
• Fundamentals of Addiction Medicine—40-Hour CME Program (MD, APP, counselors) (American Society of Addiction Medicine (ASAM))

• Pragmatic Issues for Buprenorphine Prescribers (slide set)
• The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder
• NIDAMED: Resources for Your Professional Discipline and Specialty
• Opioid Use Disorder Overview
• Risk Reduction and safe use of opioids
• Clinical Flow and Documentation
• Long-acting depot buprenorphine (Sublocade)
• Sublocade: set up and basics (operational)
• Core documentation and labs
• Dose Finding: From induction to maintenance
• Managing Staff Perceptions: Addressing Stigma and Language
• Should I Discharge this Patient
• Dreaded Phone Calls: Early Refills, Lost Meds, Precipitated Withdrawals
• Safer Injection Resources
• Use of Naltrexone for OUD

Patients in Pain

• The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use – 2015 (American Society of Addiction Medicine (ASAM)), See Part 9 (page 43): Special Populations: Individuals with Pain
• TIP 54: Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders – January 2012 (Substance Abuse and Mental Health Services Administration (SAMHSA)), Includes Literature Review and Guidance
• Treatment of Pain in Patients Taking Buprenorphine for Opioid Addiction (Palliative Care Network of Wisconsin) How do I co-manage pain? What meds do I use to manage pain?

Pregnancy

• Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants – January 2018 (Substance Abuse and Mental Health Services Administration (SAMHSA))
• Impact of MAT on opioid use disorder in pregnancy

Adolescents

• TIP 31: Screening and Assessing Adolescents for Substance Use Disorders – June 2012 (Substance Abuse and Mental Health Services Administration (SAMHSA))
• Screening Tools for Adolescent Substance Use (National Institute on Drug Abuse (NIDA))
• Medication-Assisted Treatment: Identifying the Need for Youth and Young Adult-Specific Strategies and Current Initiatives (Webinar & Audio) (Medicaid Innovation Accelerator Program (IAP)) 
• Slides
• Audio

Suicidal Thoughts and Behaviors

• TIP 50: Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment – October 2015 (Substance Abuse and Mental Health Services Administration (SAMHSA))
• Perinatal Opioid Use Disorder (OUD) ECHO Series (Hennepin Healthcare ECHO)

Trauma-Informed Care

• What is Trauma-Informed Care? (Implementation Resource Center): Comprehensive website with tools and other resources on trauma-informed care
• Trauma Informed Care Resources (Case Western Reserve University): This page contains links to numerous resources on this topic.
• Trauma-Informed Care Resources (National Council for Behavioral Health (NCBH)): This page contains a link to virtual training on this topic.
• TIP 57: Trauma-Informed Care in Behavioral Health Services – March 2014 (Substance Abuse and Mental Health Services Administration (SAMHSA)): SAMHSA guidance on addressing the impact of trauma on those experiencing it.
• Expanding Naloxone Access for Preventing Opioid Overdose – includes training resources (MN Department of Health)
• Naloxone Booklet Infographic (CA Bridge) 
• Guide to Naloxone Distribution (CA Bridge)
  CA-focused, however, includes useful/helpful tips/tools. 

Homeless

• Recommendations for the Care of Homeless Patients with Opioid Use Disorders (Health Care for the Homeless Clinicians' Network)

• Wound Care Manual
• Sex & Drug Risk Reduction Handouts

• TedTalk – Why Do Our Brains Get Addicted, Nora Volkow (TEDMed)
• PCSS Provider Mentoring Program (Providers Clinical Support System (PCSS))
• PCSS: Training Videos on Treating Opioid Use Disorder (Providers Clinical Support System (PCSS))
• Motivational Interviewing for Opioid Use Disorder (Providers Clinical Support System (PCSS))
• Addressing Stigma Around Addiction (The National Alliance of Advocates for Buprenorphine Treatment (NAABT))
• It Takes A Village: A Patient’s Journey from Opioid Use Through Recovery (ALLISON JUBA, DO CHI ST. GABRIEL PROJECT ECHO JUNE 3, 2020)

Access all MN Community ECHO presentations and resources at Hennepin Healthcare. These include:

• Integrated Opioid and Addiction Care ECHO
• Midwest Tribal ECHO
• MN Community Collaboration on Viral Hepatitis
• Perinatal Substance Use ECHO Presentations
• Race Equity and Opioid Use ECHO
• Resources for MAT Clinics

PDMP

• State PDMP Profiles and Contacts (Prescription Drug Monitoring Program Training & Technical Assistance Center (PDMPTTAC)): Includes complete and updated contact information on individual states' PDMPs and a compilation of state statutes and regulations.
• Quick Reference Guide – How to Run a Patient Request in Prescription Monitoring Program AWARxE (MN Board of Pharmacy Prescription Monitoring Program (PMP)): This explains how to run a report on a specific patient in the PMP. At a minimum, you must provide: First name, last name, date of birth, and prescription fill dates.
• PDMP Welcome Kit and Information Request Page (MN Board of Pharmacy Prescription Monitoring Program (PMP))

Confidentiality

• Substance Abuse Confidentiality Regulations (Substance Abuse and Mental Health Services Administration (SAMHSA)): Fact Sheets regarding the Substance Abuse Confidentiality Regulations and FAQ
• 42 CFR Part 2 for Practices Simplified (Substance Abuse and Mental Health Services Administration (SAMHSA))
• Substance Abuse Confidentiality and Health Information Exchange FAQs (Substance Abuse and Mental Health Services Administration (SAMHSA)): Information on how to apply the Substance Abuse Confidentiality Regulations to Health Information Exchange (HIE) – FAQs
• HIPAA Regulations 2004 (U.S. Department of Health and Human Services (U.S. DHHS))

DEA

• DEA Diversion Control Regulations website (U.S. Drug Enforcement Administration (DEA)): This page includes links to various resources.

• Decisions in Recovery: Treatment for Opioid Use Disorders (Substance Abuse and Mental Health Services Administration (SAMHSA))
• Opioid Addiction Treatment: A Guide for Patients, Families and Friends (American Society of Addiction Medicine (ASAM))
• MAT FAQs for Patients (Providers Clinical Support System (PCSS))
• MAT FAQs for Family Members (Providers Clinical Support System (PCSS))
• Early Recovery Tips for Patients (Providers Clinical Support System (PCSS))
• SAMHSA’s National Helpline (Substance Abuse and Mental Health Services Administration (SAMHSA))

• Medicines for Treating Opioid Use Disorder: What you need to know when choosing the best treatment for you (CA Bridge)
• Buprenorphine Information for Patients (Providers Clinical Support System) 
• Buprenorphine Information for Family Members (Providers Clinical Support System) 
• Buprenorphine Fact Sheet – August 2015 (Substance Abuse and Mental Health Services Administration (SAMHSA))
• Buprenorphine-Naloxone: What You Need to Know (CA Bridge)
• What is Buprenorphine Treatment Like? (The National Alliance of Advocates for Buprenorphine Treatment (NAABT))
• Sample Form Patient Responsibilities: Buprenorphine Maintenance Treatment (The Network for the Improvement of Addiction Treatment (NIATx) at the University of Wisconsin–Madison and the Treatment Research Institute (TRI) in Philadelphia): See page 49 for more information
• Naltrexone Fact Sheet (Providers Clinical Support System (PCSS))
• FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks (Current as of 9/26/17) (Food and Drug Administration (FDA)) Important: Check the FDA website frequently for new updates
• FDA Requiring Labeling Changes for Benzodiazepines: Boxed Warning to Be Updated to Include Abuse, Addiction and Other Serious Risks (Current as of 9/23/20) (Food and Drug Administration (FDA)) Important: Check FDA website frequently for new updates